Search Results 861-870 of 16531 for Ureaplasma urealyticum

  1. Head and neck cancers - Doctors and departments - Mayo Clinic

    Lehman, M.D.. Dermatologist; Dermatopathologist. Rochester, MN. Areas of focus: Skin cancer, Skin infection, Skin rashes NOS. Eric J. Lehrer ...

  2. Head and neck cancers - Doctors and departments - Mayo Clinic

    Lehman, M.D.. Dermatologist; Dermatopathologist. Rochester, MN. Areas of focus: Skin cancer, Skin infection, Skin rashes NOS. Eric J. Lehrer ...

  3. Head and neck cancers - Doctors and departments - Mayo Clinic

    Lehman, M.D.. Dermatologist; Dermatopathologist. Rochester, MN. Areas of focus: Skin cancer, Skin infection, Skin rashes NOS. Eric J. Lehrer ...

  4. Head and neck cancers - Doctors and departments - Mayo Clinic

    Lehman, M.D.. Dermatologist; Dermatopathologist. Rochester, MN. Areas of focus: Skin cancer, Skin infection, Skin rashes NOS. Eric J. Lehrer ...

  5. Head and neck cancers - Doctors and departments - Mayo Clinic

    Lehman, M.D.. Dermatologist; Dermatopathologist. Rochester, MN. Areas of focus: Skin cancer, Skin infection, Skin rashes NOS. Eric J. Lehrer ...

  6. Obstetrics and Gynecology Clinical Trials - Medical Professionals

    The purpose of this study is to determine the safety of using an autologous mesenchymal stromal cell (MSC) coated fistula plug in people with rectovaginal ...

  7. Infectious Diseases A-Z: Pertussis infections on the rise - Mayo Clinic News Network

    "Pertussis is a bacterial infection that can cause upper respiratory symptoms that can be dangerous to our younger patients but also cause a cough that can ...

  8. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Infection, Bone metastasis, Pneumothorax, Pleural effusion, Renal cell carcinoma. Show more areas of focus for John J. Schmitz, M.D. ...

  9. Adrenal cancer - Doctors and departments - Mayo Clinic

    Learn about this rare cancer that begins in the adrenal glands. Find out about symptoms, diagnosis and treatment.

  10. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy - Mayo Clinic

    ... infection, etc. Demonstration of intolerance requires no minimum dose or duration of use. Note: Non-bio-IR subjects who have received prior biologic for up ...